Is Celyad Oncology S.A. (CYAD.BR) a Buy, Sell, or Hold?
BRU : CYAD.BR
Celyad Oncology S.A.
$0.264 EUR
$0.01 (5.6%)
- Volume
- 7.76K
- Average Volume
- 15.69K
- Market Capitalization
- $11.82M
- P/E Ratio
- 12.82
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.65
- Year Low
- $0.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.92
Company Overview
BRU
Michel E. J. Lussier
Biotechnology
Healthcare
CYAD.BR
17
BE
EUR
Liquidity Metrics
0.00
1.92
1.92
0.94
0.00
Sales & Valuation
$21000
562.72
4.49
-1.71
-0.17
Profitability
$0.0179
$830K
3833.33%
3833.33%
-242.11%
18.73%
P/E Metrics
12.82
0.09
0.09
Analyst Price Target & Rating
4/5
7 Analysts
%
Financial Health Scores
-124.09
3/9
$1.68M
$4.3M
$1.86M
-$13.02M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Michel E. J. Lussier | Co-Founder & Non-Executive Director |
| Sara Zelkovic | Communications & Investor Relations Director |
| An Phan | Head of Legal |
| Philippe Dechamps | Corporate Secretary |
| David Georges | Vice President of Finance & Administration |
Poll Results
No votes yet today — be the first to share your view!
About Celyad Oncology S.A. (BRU:CYAD.BR) Stock
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is devel ... oping CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Frequently Asked Questions
-
What is the current Celyad Oncology S.A. (CYAD.BR) stock price?
-
Celyad Oncology S.A.(BRU:CYAD.BR) stock price is $0.264 in the last trading session. During the trading session, CYAD.BR stock reached the peak price of $0.65 while $0.16 was the lowest point it dropped to. The percentage change in CYAD.BR stock occurred in the recent session was 5.6% while the dollar amount for the price change in CYAD.BR stock was $0.01.
-
CYAD.BR's industry and sector of operation?
-
The BRU listed CYAD.BR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYAD.BR?
-
Michel E. J. Lussier | Co-Founder & Non-Executive Director
Sara Zelkovic | Communications & Investor Relations Director
An Phan | Head of Legal
Philippe Dechamps | Corporate Secretary
David Georges | Vice President of Finance & Administration -
How many employees does CYAD.BR have?
-
Number of CYAD.BR employees currently stands at 17. CYAD.BR operates from Axis Business Park, Mont-Saint-Guibert, WA 1435, BE.
-
Link for CYAD.BR official website?
-
Official Website of CYAD.BR is: https://www.celyad.com
-
How do I contact CYAD.BR?
-
CYAD.BR could be contacted at phone #32 1 039 41 00 and can also be accessed through its website. CYAD.BR operates from Axis Business Park, Mont-Saint-Guibert, WA 1435, BE.
-
How many shares of CYAD.BR are traded daily?
-
The average number of CYAD.BR shares traded daily for last 3 months was 15.69K.
-
What is the market cap of CYAD.BR currently?
-
The market value of CYAD.BR currently stands at $11.82M with its latest stock price at $0.264